Abstract
One of the major challenges in using neoantigen-based approaches in cancer treatment is the identification of cancer-specific neoantigens, particularly those that are shared by patients. In a recent report, Kim et al. uncover a novel source of cancer neoantigens in splicing factor mutant myeloid malignancies. These mis-spliced neoantigens offer new opportunities for engineered TCR–T cell therapies and neoantigen-based vaccines.
| Original language | English |
|---|---|
| Pages (from-to) | 611-613 |
| Number of pages | 3 |
| Journal | Trends in Cancer |
| Volume | 11 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2025 |
Bibliographical note
Publisher Copyright:© 2025 Elsevier Inc.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- CAR-T
- RNA processing
- RNA splicing
- immunotherapy
- neoantigens
Fingerprint
Dive into the research topics of 'Spliced to kill: RNA mis-splicing derived cancer neoantigens'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver